These innovative compounds represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://marckkze663937.collectblogs.com/83721198/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide